The GNRH1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the HeLa cell line, with targeted disruption of the GNRH1 gene. This loss-of-function model is provided as a mixed population of edited cells, eliminating endogenous gonadotropin-releasing hormone 1 expression. The knockout enables precise dissection of GNRH1-dependent pathways in a genetically tractable system.
The parental HeLa cells, originating from a cervical adenocarcinoma of Henrietta Lacks, are a transformed epithelial line containing human papillomavirus type 18 (HPV18) sequences. Their robust proliferation and well-characterized biology make them a versatile host for studying gene function. Although HeLa cells do not naturally express GNRH1, the introduction of a knockout creates a controlled backdrop for investigating GnRH signaling independently of hypothalamic context.
GNRH1 encodes the preprohormone processed into GnRH, the central neuropeptide of the reproductive axis. Binding of GnRH to its receptor GNRHR on gonadotropes triggers Gq/11-mediated activation of phospholipase C (PLCB) and protein kinase C (PRKCA), eliciting calcium mobilization and MAPK/ERK signaling through MAP2K1 and MAPK3. Downstream, transcription factors FOS and JUN are phosphorylated, promoting luteinizing hormone (LH) and follicle-stimulating hormone (FSH) gene expression. The GNRH1 gene is regulated by upstream signals including KISS1/KISS1R, neurokinin B, dynorphin, and estradiol feedback. In this knockout model, disruption of the ligand?Creceptor interaction silences the entire cascade, blocking LH and FSH secretion.
This knockout cell model is particularly suited for studying GNRH1 function in epithelial cancers, as GnRH and its receptor are implicated in prostate cancer and endometriosis. The HeLa background permits exploration of direct GNRH1-mediated effects on proliferation and apoptosis without interference from native hypothalamic circuitry, offering insights into hormone-driven tumor biology.
Applications include screening of GnRH analogs, reproductive toxicity assessment, and investigation of hypogonadotropic hypogonadism or Kallmann syndrome. Typical assays encompass western blotting, RT-qPCR, immunofluorescence, phospho-ERK signaling analysis, and LH/FSH secretion measurements. Co-culture with pituitary cell lines or reporter assays for gonadotropin promoters allow detailed functional studies. For further details, please contact Ascent Research.
